Table 2. Combination activity of melflufen and cytarabine or daunorubicin in HL-60 for selected concentrations (calculated according to the multiplicative Bliss model).
Concentrationmelflufen(μM) | Concentrationcytarabine(μM) | Concentrationdaunorubicin(μM) | PI melflufen(%) | PIcytarabine(%) | PIcombination(%) | PIcombinationpredicted | Interaction |
---|---|---|---|---|---|---|---|
0.030 | 0.25 | NA | 47 | 30 | 71 | 63 | S |
0.030 | 0.50 | NA | 47 | 45 | 83 | 71 | S |
0.063 | 0.25 | NA | 71 | 30 | 83 | 79 | S |
0.063 | 0.50 | NA | 71 | 45 | 88 | 84 | S |
0.030 | NA | 0.013 | 47 | 40 | 54 | 68 | SA |
0.030 | NA | 0.025 | 47 | 58 | 71 | 77 | SA |
0.063 | NA | 0.013 | 71 | 40 | 74 | 83 | SA |
0.063 | NA | 0.025 | 71 | 58 | 78 | 88 | SA |
Abbreviations: PI; percent inhibition, S; Synergy, SA; Subadditive interaction.